Therapy for Metastatic Breast Cancer, Abemaciclib, Shows Promise in Phase 2 Study

Therapy for Metastatic Breast Cancer, Abemaciclib, Shows Promise in Phase 2 Study
Treatment with abemaciclib as monotherapy induced objective tumor responses and was well-tolerated by patients with HR-positive, HER2-negative metastatic breast cancer, which may allow for prolonged treatment use. These results were detailed in the study, “MONARCH1: Results from a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as monotherapy, in patients with HR+/HER2- breast cancer, after chemotherapy for advanced disease,” recently presented at the ASCO 2016 meeting in Chicago. Abemaciclib is a CDK inhibitor selective for CDK4 and CDK6, two molecules (cyclins) involved in cell division. It is an investigational drug for various types of cancer, and was designated a breakthrough therapy by the U.S. Food and Drug Administration in October 2015. “Abemaciclib is a CDK 4/6 inhibitor,” Adam M. Brufsky, MD, PhD, professor of medicine, associate chief of hematology/oncology, and co-director of the comprehensive breast cancer center at the University of Pittsburgh, said in a news release. “It differs from palbociclib in that it really, predominately, inhibits CDK 4 and not 6.” MONARC
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.